Lei Yao

Array ( [id] => 16576618 [patent_doc_number] => 20210011019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => MPL MUTATIONS IN JAK2 V617F NEGATIVE PATIENTS WITH MYELOPROLIFERATIVE DISEASE [patent_app_type] => utility [patent_app_number] => 17/026766 [patent_app_country] => US [patent_app_date] => 2020-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17026766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806169 [patent_doc_number] => 20210128722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE [patent_app_type] => utility [patent_app_number] => 17/024425 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17024425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16589318 [patent_doc_number] => 10898560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers [patent_app_type] => utility [patent_app_number] => 17/018572 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 19 [patent_no_of_words] => 59286 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17018572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311844 [patent_doc_number] => 12037647 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Compositions and methods for detecting pancreatic cancer [patent_app_type] => utility [patent_app_number] => 17/013989 [patent_app_country] => US [patent_app_date] => 2020-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 45 [patent_no_of_words] => 14470 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17013989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17461636 [patent_doc_number] => 20220074941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => HSP90 COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/006359 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793013 [patent_doc_number] => 20210122830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE [patent_app_type] => utility [patent_app_number] => 17/003442 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569141 [patent_doc_number] => 20210008147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors [patent_app_type] => utility [patent_app_number] => 17/002116 [patent_app_country] => US [patent_app_date] => 2020-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17002116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809542 [patent_doc_number] => 12240913 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Anti-HER2/anti-4-1BB bispecific antibody and use thereof [patent_app_type] => utility [patent_app_number] => 16/939536 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 35 [patent_no_of_words] => 16071 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 427 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628764 [patent_doc_number] => 20210047417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => MICA/B ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/938554 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -160 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16938554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828324 [patent_doc_number] => 20220265628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/597553 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -142 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17597553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546746 [patent_doc_number] => 20220118087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE [patent_app_type] => utility [patent_app_number] => 16/932204 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14094 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16375128 [patent_doc_number] => 20200323970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/917381 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590564 [patent_doc_number] => 10899814 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/917230 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 39206 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590563 [patent_doc_number] => 10899813 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/917141 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 39286 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16519475 [patent_doc_number] => 10870685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/917040 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 40416 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590562 [patent_doc_number] => 10899812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/916833 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 39257 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16816811 [patent_doc_number] => 11001617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/917176 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 37 [patent_no_of_words] => 39324 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16589317 [patent_doc_number] => 10898559 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers [patent_app_type] => utility [patent_app_number] => 16/915707 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 19 [patent_no_of_words] => 59144 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19106826 [patent_doc_number] => 11959918 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Eukaryotic translation initiation factors (eIFs) as novel biomarkers in bladder cancer [patent_app_type] => utility [patent_app_number] => 16/911226 [patent_app_country] => US [patent_app_date] => 2020-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 23 [patent_no_of_words] => 11394 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437142 [patent_doc_number] => 20200354468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/900596 [patent_app_country] => US [patent_app_date] => 2020-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16900596 [rel_patent_id] =>[rel_patent_doc_number] =>)